Los Angeles, New York, Stanford University: HBY 097, new drug may weaken HIV.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D006678:HIV / Q000187:drug effects*; D054303:HIV Reverse Transcriptase; D006801:Humans; D015141:Los Angeles; D009154:Mutation; D009518:New York; D011810:Quinoxalines; D012194:RNA-Directed DNA Polymerase / Q000235:genetics; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D012495:San Francisco
D000998:Antiviral Agents; D011810:Quinoxalines; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase; C093110:HBY 097